Core Viewpoint - Company Vailizhibo-B has been included in the Hang Seng Composite Index and is expected to become a target for the Stock Connect program, attracting attention due to its core product development receiving FDA fast track designation [1][2]. Group 1: Stock Performance - According to the quarterly review results published by the Hang Seng Index Company on February 13, 2026, Vailizhibo-B will be included in the Hang Seng Composite Index, with the change effective after market close on March 6, 2026, and effective from March 9, 2026 [2]. - The inclusion in the index may lead to adjustments in the Stock Connect investment scope, potentially attracting southbound capital [2]. Group 2: Product Development Progress - LBL-024 (PD-L1/4-1BB bispecific antibody) received FDA fast track designation on January 14, 2026, for the treatment of pulmonary neuroendocrine carcinoma, having previously shown potential in Phase II or registrational clinical trials for non-small cell lung cancer and small cell lung cancer [3]. - LBL-034 (GPRC5D/CD3 bispecific antibody) received FDA fast track designation on January 27, 2026, for the treatment of relapsed/refractory multiple myeloma, highlighting the technical advantages of the company's TCE platform [3]. Group 3: Funding Dynamics - The company experienced a lock-up release for cornerstone investors on January 25, 2026, involving nine cornerstone investors (including Zhengxin Valley Capital and Tencent), with a total subscription amount of approximately HKD 542 million [4]. - During the 2025 review period, the company's average daily market capitalization was HKD 9.462 billion, exceeding the threshold of HKD 9.247 billion, meeting the conditions for inclusion in the Stock Connect program, with the final result expected to be confirmed in March 2026 [4].
维立志博-B获纳入恒生综合指数，核心产品研发获FDA快速通道资格